Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer-Reference-Cited by-同舟云学术

Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer

Published:2020-11 Issue: Volume:152 Page:117-125
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Defraene Gilles,Dankers Frank J.W.M.,Price Gareth,Schuit Ewoud,van Elmpt Wouter,Arredouani Soumia,Lambrecht Maarten^ORCID,Nuyttens Joost,Faivre-Finn Corinne^ORCID,De Ruysscher Dirk

Funder

European Union’s Seventh Framework Programme

Cancer Research UK

NIHR Biomedical Research Centre

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference41 articles.

1. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Auperin;J Clin Oncol,2010

2. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

3. Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy +/- cetuximab for stage III NSCLC;Bradley;Int J Rad Oncol Biol Phys,2017

4. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE);Eberhardt;J Clin Oncol,2015

5. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer;Senan;J Clin Oncol,2016

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosimetric and NTCP advantages of robust proton therapy over robust VMAT for Stage III NSCLC in the immunotherapy era;Physica Medica;2024-07

2. Federated Learning Survival Model and Potential Radiotherapy Decision Support Impact Assessment for Non–small Cell Lung Cancer Using Real-World Data;Clinical Oncology;2024-07

3. Letter to the editor regarding “External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts” by M. Berbée et al.;Radiotherapy and Oncology;2024-04

4. Comparison of deep inspiration breath hold and free breathing intensity modulated proton therapy of locally advanced lung cancer;Physics and Imaging in Radiation Oncology;2024-04

5. External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts;Radiotherapy and Oncology;2024-01